740-P: Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting

TYLER DUNN,YONG ZHU,NOELLE GRONROOS,LIN XIE,JOSHUA NOONE,ANDREW SARGENT,LARISA YEDIGAROVA,LIANA K. BILLINGS

DOI: https://doi.org/10.2337/db24-740-p

IF: 7.7

2024-01-01

Diabetes

Abstract:Introduction & Objective: Multiple clinical trials have shown cardiovascular benefits from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D). This study describes persistence and adherence of once weekly (OW) GLP-1 RAs use by patients with T2D and atherosclerotic cardiovascular disease (ASCVD) in a real-world setting. Methods: The study used data from the Optum Research Database from 01 Jan 2017 through 28 Feb 2023 and identified adult patients with T2D and ASCVD with ≥1 pharmacy claim for OW GLP-1 RAs. The date of the first claim was the index date and the start of a variable follow up period. Persistence was defined as the number of days from the index date to either discontinuation of OW GLP-1 RAs or end of variable follow up. Percentages of persistent patients (those without discontinuation) were reported at 6, 12, and 18 months, as well as over the full variable follow up period. Adherence, measured as proportion of days covered (PDC) over the full variable follow up period, was reported for patients with at least 6, 12, and 18 months of follow up. Results: Among a total of 29516 patients, the mean follow up duration was 535 days and mean persistence was 371 days; 63.9% of patients were persistent throughout their variable follow up period. Basic demographic and clinical characteristics were similar between persistent and non-persistent patients. At 6 months, 80.2% of patients were persistent; the percentage was 63.2% and 54.3% at 12 and 18 months, respectively. PDC was 0.72, 0.68, and 0.66 among patients with at least 6, 12, or 18 months of follow up, respectively. Conclusions: Patients had at least two-thirds of PDC and 63.9% of them were persistent throughout their follow up. Identifying factors influencing persistence and adherence is imperative to guide interventions aimed at enhancing these aspects, thereby maximizing the cardiovascular benefits derived from GLP-1 RAs. T. Dunn: Employee; Novo Nordisk. Y. Zhu: Employee; UnitedHealth Group. Stock/Shareholder; UnitedHealth Group. Other Relationship; UnitedHealth Group, Novo Nordisk. N. Gronroos: Other Relationship; UnitedHealth Group, Novo Nordisk. Stock/Shareholder; UnitedHealth Group. Employee; UnitedHealth Group. L. Xie: None. J. Noone: Employee; Novo Nordisk. A. Sargent: Other Relationship; Novo Nordisk. Employee; UnitedHealth Group. Other Relationship; UnitedHealth Group. L. Yedigarova: Employee; Novo Nordisk. Stock/Shareholder; AbbVie Inc. L.K. Billings: Advisory Panel; Novo Nordisk, Pfizer Inc. Novo Nordisk, Inc.